Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

corticosteroid fluticasone furoate

National Institute for Health and Care Excellence NICE logo

UK backs use of drugs to prevent breast cancer

Daily use of tamoxifen or raloxifene recommended in at-risk women

- PMLiVE

Boehringer files Pradaxa for new VTE indication in Europe

Seeks to add to anticoagulant’s approvals

- PMLiVE

Astellas wins EU approval for prostate cancer drug Xtandi

Will compete with J&J’s big-selling Zytiga

- PMLiVE

Sandoz takes short route for biosimilar Enbrel approval

Novartis subsidiary initiates late-stage trial to support use in chronic plaque-type psoriasis

- PMLiVE

Cost deters NICE from Sanofi’s bowel cancer drug Zaltrap

Fails to win recommendation despite patient access scheme

Novartis building

US FDA deems Novartis’ heart failure candidate a ‘breakthrough’

Serelaxin demonstrates ability to reduce shortness of breath and lower chance of dying

- PMLiVE

Sanofi and AstraZeneca form cancer research alliances with non-profits

Will work respectively with Curie Institute in France and Cancer Research UK

- PMLiVE

Novartis launches European advanced breast cancer campaign

Campaign launches with audio/visual installation

- PMLiVE

J&J acquires oncology candidate in $1bn Aragon buy

ARN-509 is in phase II development for castration resistant prostate cancer

- PMLiVE

Men’s oesophageal cancer risk “triple that of women”

New data from Cancer Research UK shines slight on 'quiet epidemic'

- PMLiVE

AstraZeneca picks location for global HQ and research base

Decides on the Cambridge Biomedical Campus in UK

- PMLiVE

AstraZeneca and NGM form diabetes/ obesity partnership

Will use MedImmune arm to develop treatments that target gastrointestinal hormones

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links